Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed Dec 12, 2025
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2025-12-10$4.10/sh−155$636→ 17,338 total
Footnotes (1)
- [F1]Includes 417 additional shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction.